• Product NameGLPG1690
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityGLPG-1690, a first-in-class autotaxin inhibitor, currently being evaluated in an exploratory phase 2a study in idiopathic pulmoN/Ary fibrosis patients.
• Target NamePDE inhibitor
• CAS No. 1628260-79-6
• Calculated MW 588.71
• Formulation C30H33FN8O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Respiratory system
  SMILES:CCC1=C(N2C=C(C=C(C2=N1)C)N3CCN(CC3)CC(=O)N4CC(C4)O)N(C)C5=NC(=C(S5)C#N)C6=CC=C(C=C6)F
  Pathways:Metabolism
  Receptor:autotaxin
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Desroy N., et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic PulmoN/Ary Fibrosis. J Med Chem. 2017 May 11;60(9):3580-3590.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting